ZVSA

ZyVersa Therapeutics, Inc. · NASDAQ

Sector Health Technology
Industry Pharmaceuticals: Major
Website zyversa.com
Employees(FY) 7
ISIN US98987D3008

Performance

+5.56%

-7.32%

-49.78%

-77.43%

-87.33%

YTD

-85.71%

Profile

ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. The company engages in the development of VAR 200, a cholesterol efflux mediator, which is in Phase 2a clinical trial to the treatment of multiple renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic nephropathy; and IC 100, a monoclonal antibody inflammasome ASC inhibitor that is in preclinical stage for treatment of multitude of inflammatory diseases. ZyVersa Therapeutics, Inc. is headquartered in Weston, Florida.

Advanced Technical Analysis

Technical Analysis of ZVSA 2024-12-20

The stock indicators reflect a predominantly neutral sentiment, with the Moving Average Score at 36 indicating bearish pressure, while the Oscillators Score at 43 and the overall Technical Score at 40 suggest a lack of strong momentum in either direction. This combination implies that the stock is currently in a consolidation phase, warranting c...

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of ZVSA

Stock Rank

Recent News & Updates

2024-12-17 18:55
ZyVersa Therapeutics' CEO, Stephen C. Glover, to Attend JPM's Healthcare Conference 2025 in San Francisco(Globenewswire)
2024-11-19 18:55
ZyVersa Therapeutics Announces Peer-Reviewed Publication Demonstrating That Inflammasome ASC Inhibitor IC 100 Protects Against Stroke-Related Cardiovascular Injury and Dysfunction in Preclinical Trial(Globenewswire)
2024-11-14 19:35
Life Sciences Investor Forum: Presentations Now Available for Online Viewing(Yahoo Finance)
2024-11-13 19:10
ZyVersa Therapeutics Reports Third Quarter, 2024 Financial Results and Provides Business Update(Globenewswire)
2024-11-11 19:35
Life Sciences Investor Forum Agenda Announced for November 14th(Yahoo Finance)
2024-11-04 18:00
ZyVersa Therapeutics Highlights Published Data Demonstrating the Potential of Inflammasome Inhibition to Protect Pancreatic Islet Beta Cells and Attenuate Progression from Obesity to Insulin Resistance and Type 2 Diabetes(Globenewswire)
2024-10-28 19:57
ZyVersa Therapeutics Highlights Review Article Supporting the Need for Drug Therapies to Treat the Inflammation of Obesity in Addition to Weight Loss Drugs(Globenewswire)
2024-10-21 19:57
ZyVersa Therapeutics Highlights Published Data Demonstrating That Obesity Results in Neuroinflammation Implicated in Development of Neurodegenerative Diseases(Globenewswire)
2024-10-16 19:50
ZyVersa Therapeutics CEO, Stephen C. Glover, Issues Letter to Shareholders Highlighting Obesity Development Plans for Inflammasome ASC Inhibitor IC 100 Over the Next Nine Months(Globenewswire)
2024-10-14 19:50
ZyVersa Therapeutics CEO, Stephen C. Glover, Was a Featured Guest on The Big Biz Show to Discuss Current Trends in the Obesity Drug Market and the Potential Role of Inflammasome Inhibitors(Globenewswire)
2024-10-06 19:55
ZyVersa Therapeutics Forms New Scientific Advisory Board to Support Development of Inflammasome ASC Inhibitor IC 100 for Obesity with Metabolic Complications(Globenewswire)
2024-08-09 09:52
ZVSA Stock Earnings: ZyVersa Therapeutics Beats EPS for Q2 2024(Investorplace)
2024-08-09 04:40
ZyVersa Therapeutics Reports Second Quarter, 2024 Financial Results and Provides Business Update(Globenewswire)
2024-08-06 19:50
ZyVersa Therapeutics Announces Published Data Supporting the Rationale for Inhibiting Inflammasome ASC with IC 100 to Control Chronic Inflammation(Globenewswire)
2024-07-28 19:45
ZyVersa Therapeutics Announces Published Data Demonstrating That Plasma Levels of Inflammasome ASC Show Promise as Biomarker of Early Cognitive Changes in Older Adults(Globenewswire)
2024-07-24 19:57
ZyVersa Therapeutics Selects Obesity and Related Metabolic Complications as Lead Indication for Inflammasome ASC Inhibitor IC 100(Globenewswire)
2024-07-17 23:18
ZyVersa Therapeutics Announces Publication Demonstrating that Inflammasome ASC Inhibitor IC 100 Restored Retinal Structure and Function in a Retinopathy of Prematurity Animal Model(Globenewswire)
2024-07-08 19:57
ZyVersa Therapeutics' CEO, Stephen C. Glover, Is an Invited Speaker at H.C. Wainwright 3rd Annual Kidney Conference to be Held Virtually on July 15, 2024(Globenewswire)
2024-05-15 11:53
ZVSA Stock Earnings: ZyVersa Therapeutics Misses EPS for Q1 2024(Investorplace)
2024-05-14 20:35
ZyVersa Therapeutics Reports First Quarter, 2024 Financial Results and Provides Business Update(Globenewswire)
2024-05-13 19:57
ZyVersa Therapeutics' CEO, Stephen C. Glover, to Participate in the 2024 BIO International Convention(Globenewswire)
2024-04-28 19:57
ZyVersa Therapeutics Announces Publication Reinforcing the Rationale for Inhibiting ASC with IC 100 to Potentially Attenuate Cardiac Comorbidities in Patients with Alzheimer's Disease(Globenewswire)
2024-04-03 19:57
ZyVersa Therapeutics Highlights Published Data Demonstrating NLRP3 Inflammasome Inhibition Has Potential to Decrease Atherosclerotic Lesions in Patients with Diabetes(Globenewswire)
2024-03-24 20:17
ZyVersa Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update(Globenewswire)
2024-03-17 19:57
ZyVersa Therapeutics Announces IRB Approval of Phase 2a Clinical Trial Protocol to Evaluate Cholesterol Efflux Mediator VAR 200 in Patients with Diabetic Kidney Disease(Globenewswire)
2024-03-13 19:57
ZyVersa Therapeutics' CEO, Stephen C. Glover to Participate in a Panel Discussion Titled Inflammation Illuminated, at Benzinga's Virtual Healthcare Summit 2024 on March 20, 2024(Globenewswire)
2024-02-28 18:57
ZyVersa Therapeutics Generated Approximately $2.7 Million From Exercise of Warrants Following Excitement Around News That Inflammasome Inhibitors Have Potential to Effectively Treat Obesity(Globenewswire)
2024-02-27 18:57
ZyVersa Therapeutics Highlights Data from Review Article Published in Nature Reinforcing IC 100's Rationale for Inhibiting ASC and ASC Specks to Attenuate Damaging Inflammation Associated with Various Conditions, Including Obesity and Its Complications(Globenewswire)
2024-02-25 18:55
Why Is ZyVersa Therapeutics (ZVSA) Stock Up 37% Today?(Investorplace)
2024-02-21 18:47
ZyVersa Therapeutics Publishes New White Paper Detailing the Role of Inflammasomes and ASC Specks in Neurological Diseases, and Data Supporting Inflammasome ASC Inhibitor IC 100 as a Potential Therapeutic Option(Globenewswire)

Page 1 of 4

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.